CONTEXT: Bone turnover markers (BTMs) may identify changes in bone remodeling within a relatively short time interval before changes in bone mineral density can be detected. New markers such as osteoprotegerin, receptor activator of nuclear factor-κB ligand, and sclerostin have emerged, but there is little information about their potential use in clinical practice. OBJECTIVES: The aim of this study was to analyze the ability of several BTMs to predict bone loss in pre- and postmenopausal women and to monitor the efficacy of treatment in osteoporotic women. DESIGN, PATIENTS, AND SETTING: We performed an observational prospective study in pre- and postmenopausal ambulatory women (n = 72 and n = 152, respectively). INTERVENTION: Postmenopausal women with osteoporosis (n = 18) were treated with risedronate and calcium. Women filled out a questionnaire and underwent bone mineral density measurement using dual-energy x-ray absorptiometry at the time of enrollment and after 1 year of follow-up. BTMs were measured at baseline, at 6 months, and after 1 year. RESULTS: Increased levels of N-terminal propeptide of type 1 procollagen (P1NP) and β-type I collagen telopeptides (CTXs) were associated with low bone mineral density in the premenopausal (P = .02 and P = .04, respectively) and postmenopausal (P = .03 and P = .02) groups. The best analytical performance to diagnose osteoporosis was for β-CTX, osteocalcin, and P1NP, with areas under the curve of 0.70 (P = .005), 0.64 (P = .048), and 0.71 (P = .003). A significant decrease was found in P1NP, osteocalcin, tartrate-resistant acid phosphatase-5b, β-CTX, and bone alkaline phosphatase after 1 year of treatment (all P < .05). CONCLUSIONS: Our data suggest that measurement of β-CTX and P1NP shows adequate analytical performance and could potentially be included in algorithms for the screening of osteoporosis. Furthermore, these two markers, along with osteocalcin and tartrate-resistant acid phosphatase-5b, are useful to monitor the response to risedronate.
CONTEXT: Bone turnover markers (BTMs) may identify changes in bone remodeling within a relatively short time interval before changes in bone mineral density can be detected. New markers such as osteoprotegerin, receptor activator of nuclear factor-κB ligand, and sclerostin have emerged, but there is little information about their potential use in clinical practice. OBJECTIVES: The aim of this study was to analyze the ability of several BTMs to predict bone loss in pre- and postmenopausal women and to monitor the efficacy of treatment in osteoporoticwomen. DESIGN, PATIENTS, AND SETTING: We performed an observational prospective study in pre- and postmenopausal ambulatory women (n = 72 and n = 152, respectively). INTERVENTION: Postmenopausal women with osteoporosis (n = 18) were treated with risedronate and calcium. Women filled out a questionnaire and underwent bone mineral density measurement using dual-energy x-ray absorptiometry at the time of enrollment and after 1 year of follow-up. BTMs were measured at baseline, at 6 months, and after 1 year. RESULTS: Increased levels of N-terminal propeptide of type 1 procollagen (P1NP) and β-type I collagen telopeptides (CTXs) were associated with low bone mineral density in the premenopausal (P = .02 and P = .04, respectively) and postmenopausal (P = .03 and P = .02) groups. The best analytical performance to diagnose osteoporosis was for β-CTX, osteocalcin, and P1NP, with areas under the curve of 0.70 (P = .005), 0.64 (P = .048), and 0.71 (P = .003). A significant decrease was found in P1NP, osteocalcin, tartrate-resistant acid phosphatase-5b, β-CTX, and bone alkaline phosphatase after 1 year of treatment (all P < .05). CONCLUSIONS: Our data suggest that measurement of β-CTX and P1NP shows adequate analytical performance and could potentially be included in algorithms for the screening of osteoporosis. Furthermore, these two markers, along with osteocalcin and tartrate-resistant acid phosphatase-5b, are useful to monitor the response to risedronate.
Authors: Jessica Bon; Yingze Zhang; Joseph K Leader; Carl Fuhrman; Subashan Perera; Divay Chandra; Marnie Bertolet; Brenda Diergaarde; Susan L Greenspan; Frank C Sciurba Journal: Ann Am Thorac Soc Date: 2018-05
Authors: Janet Brown; Emma Rathbone; Samantha Hinsley; Walter Gregory; Fatma Gossiel; Helen Marshall; Roger Burkinshaw; Helen Shulver; Hasina Thandar; Gianfilippo Bertelli; Keane Maccon; Angela Bowman; Andrew Hanby; Richard Bell; David Cameron; Robert Coleman Journal: J Natl Cancer Inst Date: 2018-08-01 Impact factor: 13.506
Authors: Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Jessica González; Macarena Rodríguez-Fraile; Pilar Rivera; Patricia Restituto; Inmaculada Colina; María de Los Desamparados Calleja; Ana B Alcaide; Aránzazu Campo; Juan Bertó; Luís M Seijo; Teresa Pérez; Javier Zulueta; Nerea Varo; Juan P de-Torres Journal: PLoS One Date: 2019-02-01 Impact factor: 3.240